MULTIPLE MYELOMA REFRACTORY
Clinical trials for MULTIPLE MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental CAR-T therapy for myeloma trial pulled before start
Disease control TerminatedThis early-phase trial aimed to test a new immune cell therapy called BCMA/GPRC5D CAR-T in people with relapsed or refractory multiple myeloma. The study was designed to check safety and dosing, but it was withdrawn before any patients were enrolled. No results are available.
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Quick-Made cancer fighter put on hold: new CAR-T study withdrawn
Disease control TerminatedThis study aimed to test a new type of CAR-T cell therapy called UF-KURE-BCMA for people with multiple myeloma that had returned or stopped responding to treatment. The therapy was made from a simple blood draw and took less time to produce than standard CAR-T cells. However, the…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New antibody combo takes on Hard-to-Treat myeloma
Disease control ENROLLING_BY_INVITATIONThis study tests a new antibody drug called HuL001, given together with two standard myeloma drugs (lenalidomide and dexamethasone), in 21 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if the combination is safe and can s…
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: HuniLife Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Online tool aims to empower myeloma patients
Knowledge-focused OngoingThis study tests whether a health technology platform called All4Cure can help people with multiple myeloma become more active in managing their own health. Two hundred participants will fill out surveys about their symptoms and how confident they feel in handling their care. No …
Matched conditions: MULTIPLE MYELOMA REFRACTORY
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:51 UTC